Press Release
Akebia Initiates Phase 1 Study of First-In-Class HPTPβ Inhibitor for Diabetic Macular Edema
Akebia Initiates Phase 1 Study of First-In-Class HPTPβ Inhibitor for Diabetic Macular Edema
November 21, 2011 at 12:00 AM EST
Print Page
Email Page
Contact IR
Email Alerts
Tear Sheet
Akebia Therapeutics, Inc.
245 First Street, Suite 1400
Cambridge, MA 02142
+1 617.871.2098 phone
+1 617.871.2099 fax